about
Variation of breast cancer risk among BRCA1/2 carriers.Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report.Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study.Rare germline mutations in PALB2 and breast cancer risk: a population-based study.Variants in activators and downstream targets of ATM, radiation exposure, and contralateral breast cancer risk in the WECARE study.Assessment of rare BRCA1 and BRCA2 variants of unknown significance using hierarchical modelingSingle nucleotide polymorphisms associated with risk for contralateral breast cancer in the Women's Environment, Cancer, and Radiation Epidemiology (WECARE) StudyAdjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancerReproductive factors and risk of contralateral breast cancer by BRCA1 and BRCA2 mutation status: results from the WECARE studyPopulation-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2.Radiation exposure, the ATM Gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study.Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study.Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study.Alcohol intake and cigarette smoking and risk of a contralateral breast cancer: The Women's Environmental Cancer and Radiation Epidemiology StudyVariants in the ATM gene associated with a reduced risk of contralateral breast cancer.
P50
Q24646346-33860DEA-06B7-4A9A-8807-387763854148Q30410984-BF26F02E-2AA5-4733-B08B-6DE30FEC5B65Q30415050-A188FDDF-B4B3-4C4A-8A61-41124411FA07Q30417260-31ECC385-E2F7-420F-B3F9-282F24A357CCQ30423128-260B7F6C-6111-4464-8DB0-CD6319861EA6Q30426205-578F83D6-58CB-474E-888F-5235B22E5018Q30427359-F8B739B1-7C47-4D09-A229-2CE4E8A1C366Q30430808-DB7B50DA-6A2E-4D9B-AA3E-42BC53BD3325Q30432062-A9786DED-B10E-4835-AC52-3C1AF01F6512Q30432372-8C054DD9-146C-4F5D-9D78-D11785CEDDDBQ30432746-B22E24F4-1DB1-458E-A2B2-4B6C5957DE32Q30433040-E348E966-FDB4-4E46-88BE-0A31A3464E35Q30433319-863AB4CD-6FAA-439A-8C58-7BE1441A2124Q30436439-7E84C5EA-5B08-489E-BEB0-61786CF06338Q30438940-87F440BA-C38F-426B-997A-8D161C193636
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Marinela Capanu
@ast
Marinela Capanu
@en
Marinela Capanu
@es
Marinela Capanu
@nl
Marinela Capanu
@sl
type
label
Marinela Capanu
@ast
Marinela Capanu
@en
Marinela Capanu
@es
Marinela Capanu
@nl
Marinela Capanu
@sl
prefLabel
Marinela Capanu
@ast
Marinela Capanu
@en
Marinela Capanu
@es
Marinela Capanu
@nl
Marinela Capanu
@sl